Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Drug Metabolism > Orforglipron for Sale > Orforglipron oral CAS 9002-72-6
Orforglipron oral CAS 9002-72-6 buy - large image1
Orforglipron oral CAS 9002-72-6 buy - image1

Orforglipron oral CAS 9002-72-6

FDA 27 Inquiries

Unit Price: Get Latest Price
CAS No.:

2212020-52-3

Port:

China

Packaging:

10g/bag;100g/bag

Price valid (until):

2026-01-13

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Semaglutide,Tirzepatide,Retatrutide,Melanotan,Melatonine,Coenzyme Q10

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

    Items Specifications






    Certificates

    Basic Info
    Product Name:

    Orforglipron

    Other Name:

    1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron(LY3502970);LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833

    CAS No.:

    2212020-52-3

    Molecular Formula:

    C48H48F2N10O5

    InChIKeys:

    USUWIEBBBWHKNI-BBGRWQLENA-N

    Molecular Weight:

    882.97

    EC Number:

    278-636-5

    Color/Form:

    Off-white to light yellow

    Categories:

    Drug Metabolism

    Characteristics
    Density:

    1.50±0.1 g/cm3(Predicted)

    PKA:

    7.33±0.20(Predicted)

    Critical Temperature & Pressure:

    Store at -20°C

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Semaglutide,Tirzepatide,Retatrutide,Melanotan,Melatonine,Coenzyme Q10

    Location:

    Building 1, No.15, Xingling Str., Xingqiao Str., Linping Dist., Hangzhou, China

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,100% TT in advance

    Average lead Time:

    10

    Total Annual Revenue:

    $5 million-$10 million

    Total Employees:

    101-200

    Year of Establishment:

    2014

    Deepharma, founded in 2014 by a group of professionals from fortune 500 with many years of experience, is a dynamically developing high-tech pharmaceutical enterprise of production and distribution of ingredient substances and dietary supplements. In spite of the 10 years' young age for the pharmaceutical industry, we has already filled a niche on the domestic and abroad market and continues to expand it.

    We are eager to bring added value and constant search for better solutions. Cooperating with CPU and ZJUT graduate school and other institutes, it brings continuously power to innovate in R&D process. We would keep introducing new technology and latest product to make lives better.


    All these products have been specifically formulated for particular health and sector needs.
    Key areas of expertise are:
    Custom peptides;
    Anti-aging peptides;
    Whitening peptides;
    Antioxidant;
    Sleep aid and etc.
    Products are either API, cosmetic ingredients or food supplements by registration category. Most are ready with GMP, DMF, ISO and TDS. Welcome to your cooperation!
  • Inquiry History
    27 Inquiries
    Country Product Purchase Quantity Date Posted
    Bulgaria

    orforglipron

    1 KG Aug 27, 2025
    Austria

    Orforglipron

    1000 MT Jun 12, 2026
    Switzerland

    Orforglipron

    10 MG Apr 25, 2026
    United States

    Orforglipron

    20 G Apr 3, 2026
    United States

    Orforglipron

    10 G Mar 29, 2026
    United States

    oforglipron

    3 KG Jul 4, 2025
    United States

    Orforglipron

    1 G Jun 23, 2026
    Belgium

    Orforglipron

    1 G Jun 14, 2026
    Puerto Rico

    Orforglipron

    1 G Mar 2, 2026
    United States

    Orforglipron

    10 G Oct 24, 2025
    United States

    Orforglipron

    1 G Sep 30, 2025
    United States

    Orforglipron

    1 G Sep 26, 2025
    United States

    Orforglipron

    1 G Sep 26, 2025
    United States

    orforglipron

    1 MT Sep 20, 2025
    United States

    Orforglipron

    1 KG Apr 18, 2025
    Canada

    LY-3502970

    10 G Feb 26, 2026
    United States

    Orforglipron

    200 PCS Jun 18, 2026
    United States

    orforglipron

    10 G Apr 20, 2026
    United States

    Orforglipron

    10 G Apr 6, 2026
    United States

    orforglipron

    1 G Mar 24, 2026
    • 1
    • 2
    • Go to Page Go
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.